Glioblastoma Assay Optimization (CPRIT Grant)
Glioblastoma (GBM)
Key Facts
About SingleCell Biotechnology
SingleCell Biotechnology is an early-stage biotech with a platform technology focused on the most aggressive and treatment-resistant aspects of cancer. Its core innovation is a suite of assays that capture and analyze single cancer stem cells in states of dormancy, migration, and clonogenic growth, providing high-content imaging and downstream multi-omic profiling capabilities. The company, which licensed its foundational technology from UT Southwestern Medical Center, is pre-revenue and actively seeking partnerships with pharmaceutical and research organizations to apply its platform in drug screening and target identification, initially in glioblastoma and breast cancer. Its progress is supported by non-dilutive funding, including a grant from the Cancer Prevention and Research Institute of Texas (CPRIT).
View full company profileTherapeutic Areas
Other Glioblastoma (GBM) Drugs
| Drug | Company | Phase |
|---|---|---|
| DB102 (Enzastaurin) | Denovo Biopharma | Phase 3 |
| GlioGuard Therapeutic & Diagnostic System | GlioGuard | Pre-clinical |
| DOC1021 | Diakonos Oncology | Phase 2 |
| Lead CAR-T Program | Kiragen Bio | Pre-clinical |
| GBM Immunotherapy (with SandboxAQ) | iOncologi | Pre-clinical |
| DCVax®-L | Northwest Biotherapeutics | Phase 3 |
| Lucicebtide (ST101) | Sapience Therapeutics | Phase 2 |
| Lead Program (unspecified) | BlueHaven Therapeutics | Preclinical |
| TLX101 (Pixclara® / 131I-IPA) | Telix Pharmaceuticals | Phase 3 |
| Paxalisib | Kazia Therapeutics | Phase II/III |